{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:28:53Z","timestamp":1780450133143,"version":"3.54.1"},"reference-count":80,"publisher":"Sociedade Brasileira de Pneumologia e Tisiologia","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Bras Pneumol."],"abstract":"<jats:p>This review aimed to provide an overview of pulmonary arteriovenous malformations, including the major clinical and radiological presentations, investigation, and treatment algorithm of the condition. The primary etiology of pulmonary arteriovenous malformations is hereditary hemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber syndrome, with mutations in the ENG gene on chromosome 9 (HHT type 1) or in the ACVRL1\/ALK1 complex (HHT type 2). Epistaxis should always be evaluated when repeated, when associated with anemia, and in some cases of hypoxemia. In the investigation, contrast echocardiography and chest CT are essential for evaluating this condition. Embolization is the best treatment choice, especially for correction in cases of hypoxemia or to avoid systemic infections. Finally, disease management was addressed in special conditions such as pregnancy. CT follow-up should be performed every 3-5 years, depending on the size of the afferent and efferent vessels, and antibiotic prophylactic care should always be oriented. Ultimately, knowledge of the disease by health professionals is a crucial point for the early diagnosis of these patients in clinical practice, which can potentially modify the natural course of the disease.<\/jats:p>","DOI":"10.36416\/1806-3756\/e20220359","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T15:17:05Z","timestamp":1681312625000},"page":"e20220359","source":"Crossref","is-referenced-by-count":12,"title":["Update on pulmonary arteriovenous malformations"],"prefix":"10.36416","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2199-9525","authenticated-orcid":false,"given":"William","family":"Salibe-Filho1","sequence":"first","affiliation":[{"name":"1. Divis\u00e3o de Pneumologia, Instituto do Cora\u00e7\u00e3o \u2013 InCor \u2013 Hospital das Clinicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2112-6254","authenticated-orcid":false,"given":"Francini","family":"Rossetto de Oliveira1","sequence":"additional","affiliation":[{"name":"1. Divis\u00e3o de Pneumologia, Instituto do Cora\u00e7\u00e3o \u2013 InCor \u2013 Hospital das Clinicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8642-5354","authenticated-orcid":false,"given":"Mario","family":"Terra-Filho1","sequence":"additional","affiliation":[{"name":"1. Divis\u00e3o de Pneumologia, Instituto do Cora\u00e7\u00e3o \u2013 InCor \u2013 Hospital das Clinicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22288","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1.            Wong HH, Chan RP, Klatt R, Faughnan ME. Idiopathic pulmonary arteriovenous malformations: clinical and imaging characteristics. Eur Respir J. 2011;38(2):368-375. https:\/\/doi.org\/10.1183\/09031936.00075110","DOI":"10.1183\/09031936.00075110"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2.            Faughnan ME, Granton JT, Young LH. The pulmonary vascular complications of hereditary haemorrhagic telangiectasia. Eur Respir J. 2009;33(5):1186-1194. https:\/\/doi.org\/10.1183\/09031936.00061308","DOI":"10.1183\/09031936.00061308"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3.            Gupta P, Mordin C, Curtis J, Hughes JM, Shovlin CL, Jackson JE. Pulmonary arteriovenous malformations: effect of embolization on right-to-left shunt, hypoxemia, and exercise tolerance in 66 patients. AJR Am J Roentgenol. 2002;179(2):347-355. https:\/\/doi.org\/10.2214\/ajr.179.2.1790347","DOI":"10.2214\/ajr.179.2.1790347"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4.            Shovlin CL. Pulmonary arteriovenous malformations. Am J Respir Crit Care Med. 2014;190(11):1217-1228. https:\/\/doi.org\/10.1164\/rccm.201407-1254CI","DOI":"10.1164\/rccm.201407-1254ci"},{"key":"ref4","unstructured":"5.            Sutton H. Epistaxis as an indication of impaired nutrition and of degeneration of the vascular system. Med Mirror. 1864:769-81."},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6.            Fuchizaki U, Miyamori H, Kitagawa S, Kaneko S, Kobayashi K. Hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease). Lancet. 2003;362(9394):1490-1494. https:\/\/doi.org\/10.1016\/S0140-6736(03)14696-X","DOI":"10.1016\/s0140-6736(03)14696-x"},{"key":"ref6","unstructured":"7.            Rendu H. \u00c9pistaxis r\u00e9p\u00e9t\u00e9es chez un sujet porteur de petits angiomes cutan\u00e9s et muqueux. Gaz des H\u00f4pitaux. 1896;69:1322-3."},{"key":"ref7","unstructured":"8.            Osler W. On a family form of recurring epistaxis, associated with multiple telangiectases of the skin and mucous membranes. Bull Johns Hopkins Hosp. 1901;12:333-7."},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9.            Weber FP. Multiple hereditary developmental angiomata (telangiectases) of the skin and mucous membranes associated with recurring haemorrhages. Lancet 1907170(4377):160-162.","DOI":"10.1016\/s0140-6736(00)32590-9"},{"key":"ref9","unstructured":"10.          Hanes FM. Multiple hereditary telangiectases causes hemorrhage (hereditary hemorrhagic telangiectasia). Bull Johns Hopkins Hosp. 1909;20:63-73."},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11.          Nakayama M, Nawa T, Chonan T, Endo K, Morikawa S, Bando M, et al. Prevalence of pulmonary arteriovenous malformations as estimated by low-dose thoracic CT screening. Intern Med. 2012;51(13):1677-1681. https:\/\/doi.org\/10.2169\/internalmedicine.51.7305","DOI":"10.2169\/internalmedicine.51.7305"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12.          Majumdar S, McWilliams JP. Approach to Pulmonary Arteriovenous Malformations: A Comprehensive Update. J Clin Med. 2020;9(6):1927. https:\/\/doi.org\/10.3390\/jcm9061927","DOI":"10.3390\/jcm9061927"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13.          Saboo SS, Chamarthy M, Bhalla S, Park H, Sutphin P, Kay F, et al. Pulmonary arteriovenous malformations: diagnosis. Cardiovasc Diagn Ther. 2018;8(3):325-337. https:\/\/doi.org\/10.21037\/cdt.2018.06.01","DOI":"10.21037\/cdt.2018.06.01"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14.          LINDSKOG GE, LIEBOW A, KAUSEL H, JANZEN A. Pulmonary arteriovenous aneurysm. Ann Surg. 1950;132(4):591-610. https:\/\/doi.org\/10.1097\/00000658-195010000-00002","DOI":"10.1097\/00000658-195010000-00002"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15.          Shovlin CL, Sodhi V, McCarthy A, Lasjaunias P, Jackson JE, Sheppard MN. Estimates of maternal risks of pregnancy for women with hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): suggested approach for obstetric services. BJOG. 2008;115(9):1108-1115. https:\/\/doi.org\/10.1111\/j.1471-0528.2008.01786.x","DOI":"10.1111\/j.1471-0528.2008.01786.x"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16.          McDonald MT, Papenberg KA, Ghosh S, Glatfelter AA, Biesecker BB, Helmbold EA, et al. A disease locus for hereditary haemorrhagic telangiectasia maps to chromosome 9q33-34. Nat Genet. 1994;6(2):197-204. https:\/\/doi.org\/10.1038\/ng0294-197","DOI":"10.1038\/ng0294-197"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17.          Abdalla SA, Letarte M. Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. J Med Genet. 2006;43(2):97-110. https:\/\/doi.org\/10.1136\/jmg.2005.030833","DOI":"10.1136\/jmg.2005.030833"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18.          Vorselaars VMM, Hosman AE, Westermann CJJ, Snijder RJ, Mager JJ, Goumans MJ, et al. Pulmonary Arterial Hypertension and Hereditary Haemorrhagic Telangiectasia. Int J Mol Sci. 2018;19(10):3203. https:\/\/doi.org\/10.3390\/ijms19103203","DOI":"10.3390\/ijms19103203"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19.          Shovlin CL, Simeoni I, Downes K, Frazer ZC, Megy K, Bernabeu-Herrero ME, et al. Mutational and phenotypic characterization of hereditary hemorrhagic telangiectasia. Blood. 2020;136(17):1907-1918. https:\/\/doi.org\/10.1182\/blood.2019004560","DOI":"10.1182\/blood.2019004560"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20.          Shovlin CL, Condliffe R, Donaldson JW, Kiely DG, Wort SJ; British Thoracic Society. British Thoracic Society Clinical Statement on Pulmonary Arteriovenous Malformations. Thorax. 2017;72(12):1154-1163. https:\/\/doi.org\/10.1136\/thoraxjnl-2017-210764","DOI":"10.1136\/thoraxjnl-2017-210764"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21.          Duncan BW, Desai S. Pulmonary arteriovenous malformations after cavopulmonary anastomosis. Ann Thorac Surg. 2003;76(5):1759-1766. https:\/\/doi.org\/10.1016\/S0003-4975(03)00450-8","DOI":"10.1016\/S0003-4975(03)00450-8"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22.          Guttmacher AE, Marchuk DA, White RI Jr. Hereditary hemorrhagic telangiectasia. N Engl J Med. 1995;333(14):918-924. https:\/\/doi.org\/10.1056\/NEJM199510053331407","DOI":"10.1056\/nejm199510053331407"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23.          dos Santos JW, Dalcin TC, Neves KR, Mann KC, Pretto GL, Bertolazi AN. Hereditary hemorrhagic telangiectasia: a rare cause of severe anemia. J Bras Pneumol. 2007;33(1):109-112. https:\/\/doi.org\/10.1590\/S1806-37132007000100020","DOI":"10.1590\/s1806-37132007000100020"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"24.          Shovlin CL, Sulaiman NL, Govani FS, Jackson JE, Begbie ME. Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism. Thromb Haemost. 2007;98(5):1031-1039. https:\/\/doi.org\/10.1160\/TH07-01-0064","DOI":"10.1160\/TH07-01-0064"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"25.          Faughnan ME, Mager JJ, Hetts SW, Palda VA, Lang-Robertson K, Buscarini E, et al. Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. Ann Intern Med. 2020;173(12):989-1001. https:\/\/doi.org\/10.7326\/M20-1443","DOI":"10.7326\/M20-1443"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"26.          Dupuis-Girod S, Cottin V, Shovlin CL. The Lung in Hereditary Hemorrhagic Telangiectasia. Respiration. 2017;94(4):315-330. https:\/\/doi.org\/10.1159\/000479632","DOI":"10.1159\/000479632"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"27.          Cottin V, Plauchu H, Bayle JY, Barthelet M, Revel D, Cordier JF. Pulmonary arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia. Am J Respir Crit Care Med. 2004;169(9):994-1000. https:\/\/doi.org\/10.1164\/rccm.200310-1441OC","DOI":"10.1164\/rccm.200310-1441OC"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"28.          Salibe-Filho W, Piloto BM, Oliveira EP, Castro MA, Affonso BB, Terra-Filho M, et al. Pulmonary arteriovenous malformations: diagnostic and treatment characteristics. J Bras Pneumol. 2019;45(4):e20180137. https:\/\/doi.org\/10.1590\/1806-3713\/e20180137","DOI":"10.1590\/1806-3713\/e20180137"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"29.          Contegiacomo A, Del Ciello A, Rella R, Attempati N, Coppolino D, Larici AR, et al. Pulmonary arteriovenous malformations: what the interventional radiologist needs to know. Radiol Med. 2019;124(10):973-988. https:\/\/doi.org\/10.1007\/s11547-019-01051-7","DOI":"10.1007\/s11547-019-01051-7"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"30.          Velthuis S, Buscarini E, van Gent MWF, Gazzaniga P, Manfredi G, Danesino C, et al. Grade of pulmonary right-to-left shunt on contrast echocardiography and cerebral complications: a striking association. Chest. 2013;144(2):542-548. https:\/\/doi.org\/10.1378\/chest.12-1599","DOI":"10.1378\/chest.12-1599"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"31.          Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet. 2000;91(1):66-67. https:\/\/doi.org\/10.1002\/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P","DOI":"10.1002\/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"32.          van Gent MW, Velthuis S, Post MC, Snijder RJ, Westermann CJ, Letteboer TG, et al. Hereditary hemorrhagic telangiectasia: how accurate are the clinical criteria?. Am J Med Genet A. 2013;161A(3):461-466. https:\/\/doi.org\/10.1002\/ajmg.a.35715","DOI":"10.1002\/ajmg.a.35715"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"33.          Faughnan ME, Palda VA, Garcia-Tsao G, Geisthoff UW, McDonald J, Proctor DD, et al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet. 2011;48(2):73-87. https:\/\/doi.org\/10.1136\/jmg.2009.069013","DOI":"10.1136\/jmg.2009.069013"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"34.          Velthuis S, Buscarini E, Gossage JR, Snijder RJ, Mager JJ, Post MC. Clinical implications of pulmonary shunting on saline contrast echocardiography. J Am Soc Echocardiogr. 2015;28(3):255-263. https:\/\/doi.org\/10.1016\/j.echo.2014.12.008","DOI":"10.1016\/j.echo.2014.12.008"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"35.          Lacombe P, Lacout A, Marcy PY, Binsse S, Sellier J, Bensalah M, et al. Diagnosis and treatment of pulmonary arteriovenous malformations in hereditary hemorrhagic telangiectasia: An overview. Diagn Interv Imaging. 2013;94(9):835-848. https:\/\/doi.org\/10.1016\/j.diii.2013.03.014","DOI":"10.1016\/j.diii.2013.03.014"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"36.          Gill SS, Roddie ME, Shovlin CL, Jackson JE. Pulmonary arteriovenous malformations and their mimics. Clin Radiol. 2015;70(1):96-110. https:\/\/doi.org\/10.1016\/j.crad.2014.09.003","DOI":"10.1016\/j.crad.2014.09.003"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"37.          Pierucci P, Murphy J, Henderson KJ, Chyun DA, White RI Jr. New definition and natural history of patients with diffuse pulmonary arteriovenous malformations: twenty-seven-year experience. Chest. 2008;133(3):653-661. https:\/\/doi.org\/10.1378\/chest.07-1949","DOI":"10.1378\/chest.07-1949"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"38.          Boussel L, Cernicanu A, Geerts L, Gamondes D, Khouatra C, Cottin V, et al. 4D time-resolved magnetic resonance angiography for noninvasive assessment of pulmonary arteriovenous malformations patency. J Magn Reson Imaging. 2010;32(5):1110-1116. https:\/\/doi.org\/10.1002\/jmri.22384","DOI":"10.1002\/jmri.22384"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"39.          Kritharis A, Al-Samkari H, Kuter DJ. Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist\u2019s perspective. Haematologica. 2018;103(9):1433-1443. https:\/\/doi.org\/10.3324\/haematol.2018.193003","DOI":"10.3324\/haematol.2018.193003"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"40.          Gaillard S, Dupuis-Girod S, Boutitie F, Rivi\u00e8re S, Morini\u00e8re S, Hatron PY, et al. Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease. J Thromb Haemost. 2014;12(9):1494-1502. https:\/\/doi.org\/10.1111\/jth.12654","DOI":"10.1111\/jth.12654"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"41.          Geisthoff UW, Seyfert UT, K\u00fcbler M, Bieg B, Plinkert PK, K\u00f6nig J. Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study. Thromb Res. 2014;134(3):565-571. https:\/\/doi.org\/10.1016\/j.thromres.2014.06.012","DOI":"10.1016\/j.thromres.2014.06.012"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"42.          Al-Samkari H. Hereditary hemorrhagic telangiectasia: systemic therapies, guidelines, and an evolving standard of care. Blood. 2021;137(7):888-895. https:\/\/doi.org\/10.1182\/blood.2020008739","DOI":"10.1182\/blood.2020008739"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"43.          Thalgott JH, Dos-Santos-Luis D, Hosman AE, Martin S, Lamand\u00e9 N, Bracquart D, et al. Decreased Expression of Vascular Endothelial Growth Factor Receptor 1 Contributes to the Pathogenesis of Hereditary Hemorrhagic Telangiectasia Type 2. Circulation. 2018;138(23):2698-2712. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.033062","DOI":"10.1161\/CIRCULATIONAHA.117.033062"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"44.          Al-Samkari H, Kritharis A, Rodriguez-Lopez JM, Kuter DJ. Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia. J Intern Med. 2019;285(2):223-231. https:\/\/doi.org\/10.1111\/joim.12832","DOI":"10.1111\/joim.12832"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"45.          Invernizzi R, Quaglia F, Klersy C, Pagella F, Ornati F, Chu F, et al. Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study. Lancet Haematol. 2015;2(11):e465-e473. https:\/\/doi.org\/10.1016\/S2352-3026(15)00195-7","DOI":"10.1016\/S2352-3026(15)00195-7"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"46.          Terry PB, Barth KH, Kaufman SL, White RI Jr. Balloon embolization for treatment of pulmonary arteriovenous fistulas. N Engl J Med. 1980;302(21):1189-1190. https:\/\/doi.org\/10.1056\/NEJM198005223022107","DOI":"10.1056\/NEJM198005223022107"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"47.          Mason CG, Shovlin CL. Flight-related complications are infrequent in patients with hereditary haemorrhagic telangiectasia\/pulmonary arteriovenous malformations, despite low oxygen saturations and anaemia. Thorax. 2012;67(1):80-81. https:\/\/doi.org\/10.1136\/thoraxjnl-2011-201027","DOI":"10.1136\/thoraxjnl-2011-201027"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"48.          Pollak JS, Saluja S, Thabet A, Henderson KJ, Denbow N, White RI Jr. Clinical and anatomic outcomes after embolotherapy of pulmonary arteriovenous malformations. J Vasc Interv Radiol. 2006;17(1):35-45. https:\/\/doi.org\/10.1097\/01.RVI.0000191410.13974.B6","DOI":"10.1097\/01.RVI.0000191410.13974.B6"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"49.          Letourneau-Guillon L, Faughnan ME, Soulez G, Giroux MF, Oliva VL, Boucher LM, et al. Embolization of pulmonary arteriovenous malformations with amplatzer vascular plugs: safety and midterm effectiveness. J Vasc Interv Radiol. 2010;21(5):649-656. https:\/\/doi.org\/10.1016\/j.jvir.2010.01.026","DOI":"10.1016\/j.jvir.2010.01.026"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"50.          Woodward CS, Pyeritz RE, Chittams JL, Trerotola SO. Treated pulmonary arteriovenous malformations: patterns of persistence and associated retreatment success. Radiology. 2013;269(3):919-926. https:\/\/doi.org\/10.1148\/radiol.13122153","DOI":"10.1148\/radiol.13122153"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"51.          Trerotola SO, Pyeritz RE. Does use of coils in addition to amplatzer vascular plugs prevent recanalization?. AJR Am J Roentgenol. 2010;195(3):766-771. https:\/\/doi.org\/10.2214\/AJR.09.3953","DOI":"10.2214\/AJR.09.3953"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"52.          Tau N, Atar E, Mei-Zahav M, Bachar GN, Dagan T, Birk E, et al. Amplatzer Vascular Plugs Versus Coils for Embolization of Pulmonary Arteriovenous Malformations in Patients with Hereditary Hemorrhagic Telangiectasia. Cardiovasc Intervent Radiol. 2016;39(8):1110-1114. https:\/\/doi.org\/10.1007\/s00270-016-1357-7","DOI":"10.1007\/s00270-016-1357-7"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"53.          Shovlin CL, Buscarini E, Hughes JMB, Allison DJ, Jackson JE. Long-term outcomes of patients with pulmonary arteriovenous malformations considered for lung transplantation, compared with similarly hypoxaemic cohorts. BMJ Open Respir Res. 2017;4(1):e000198. https:\/\/doi.org\/10.1136\/bmjresp-2017-000198","DOI":"10.1136\/bmjresp-2017-000198"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"54.          Livesey JA, Manning RA, Meek JH, Jackson JE, Kulinskaya E, Laffan MA, et al. Low serum iron levels are associated with elevated plasma levels of coagulation factor VIII and pulmonary emboli\/deep venous thromboses in replicate cohorts of patients with hereditary haemorrhagic telangiectasia. Thorax. 2012;67(4):328-333. https:\/\/doi.org\/10.1136\/thoraxjnl-2011-201076","DOI":"10.1136\/thoraxjnl-2011-201076"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"55.          Shovlin CL. Circulatory contributors to the phenotype in hereditary hemorrhagic telangiectasia. Front Genet. 2015;6:101. https:\/\/doi.org\/10.3389\/fgene.2015.00101","DOI":"10.3389\/fgene.2015.00101"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"56.          Edwards CP, Shehata N, Faughnan ME. Hereditary hemorrhagic telangiectasia patients can tolerate anticoagulation. Ann Hematol. 2012;91(12):1959-1968. https:\/\/doi.org\/10.1007\/s00277-012-1553-8","DOI":"10.1007\/s00277-012-1553-8"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"57.          Limeres Posse J, \u00c1lvarez Fern\u00e1ndez M, Fern\u00e1ndez Feijoo J, Medina Henr\u00edquez J, Lockhart PB, Chu VH, et al. Intravenous amoxicillin\/clavulanate for the prevention of bacteraemia following dental procedures: a randomized clinical trial. J Antimicrob Chemother. 2016;71(7):2022-2030. https:\/\/doi.org\/10.1093\/jac\/dkw081","DOI":"10.1093\/jac\/dkw081"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"58.          Shovlin C, Bamford K, Wray D. Post-NICE 2008: Antibiotic prophylaxis prior to dental procedures for patients with pulmonary arteriovenous malformations (PAVMs) and hereditary haemorrhagic telangiectasia. Br Dent J. 2008;205(10):531-533. https:\/\/doi.org\/10.1038\/sj.bdj.2008.978","DOI":"10.1038\/sj.bdj.2008.978"},{"key":"ref58","unstructured":"59.          McDonald J, Stevenson DA. Hereditary Hemorrhagic Telangiectasia. 2000 Jun 26 [updated 2021 Nov 24]. In: Adam MP, Everman DB, Mirzaa GM, et al., editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2023. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1351\/"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"60.          Ryan DJ, O\u2019Connor TM, Murphy MM, Brady AP. Follow-up interval for small untreated pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia. Clin Radiol. 2017;72(3):236-241. https:\/\/doi.org\/10.1016\/j.crad.2016.12.002","DOI":"10.1016\/j.crad.2016.12.002"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"61.          Curnes NR, Desjardins B, Pyeritz R, Chittams J, Sienko D, Trerotola SO. Lack of Growth of Small (\u22642 mm Feeding Artery) Untreated Pulmonary Arteriovenous Malformations in Patients with Hereditary Hemorrhagic Telangiectasia. J Vasc Interv Radiol. 2019;30(8):1259-1264. https:\/\/doi.org\/10.1016\/j.jvir.2019.04.009","DOI":"10.1016\/j.jvir.2019.04.009"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"62.          Lee WL, Graham AF, Pugash RA, Hutchison SJ, Grande P, Hyland RH, et al. Contrast echocardiography remains positive after treatment of pulmonary arteriovenous malformations. Chest. 2003;123(2):351-358. https:\/\/doi.org\/10.1378\/chest.123.2.351","DOI":"10.1378\/chest.123.2.351"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"63.          Kawai T, Shimohira M, Kan H, Hashizume T, Ohta K, Kurosaka K, et al. Feasibility of time-resolved MR angiography for detecting recanalization of pulmonary arteriovenous malformations treated with embolization with platinum coils. J Vasc Interv Radiol. 2014;25(9):1339-1347. https:\/\/doi.org\/10.1016\/j.jvir.2014.06.003","DOI":"10.1016\/j.jvir.2014.06.003"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"64.          Hamamoto K, Matsuura K, Chiba E, Okochi T, Tanno K, Tanaka O. Feasibility of Non-contrast-enhanced MR Angiography Using the Time-SLIP Technique for the Assessment of Pulmonary Arteriovenous Malformation. Magn Reson Med Sci. 2016;15(3):253-265. https:\/\/doi.org\/10.2463\/mrms.mp.2015-0069","DOI":"10.2463\/mrms.mp.2015-0069"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"65.          Khan SN, McWilliams JP, Bista BB, Kee S, Finn JP. Comparison of Ferumoxytol-enhanced MR Angiography and CT Angiography for the Detection of Pulmonary Arteriovenous Malformations in Hereditary Hemorrhagic Telangiectasia: Initial Results. Radiol Cardiothorac Imaging. 2020;2(2):e190077. https:\/\/doi.org\/10.1148\/ryct.2020190077","DOI":"10.1148\/ryct.2020190077"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"66.          Robert F, Desroches-Castan A, Bailly S, Dupuis-Girod S, Feige JJ. Future treatments for hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis. 2020;15(1):4. https:\/\/doi.org\/10.1186\/s13023-019-1281-4","DOI":"10.1186\/s13023-019-1281-4"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"67.          Kim YH, Kim MJ, Choe SW, Sprecher D, Lee YJ, P Oh S. Selective effects of oral antiangiogenic tyrosine kinase inhibitors on an animal model of hereditary hemorrhagic telangiectasia. J Thromb Haemost. 2017;15(6):1095-1102. https:\/\/doi.org\/10.1111\/jth.13683","DOI":"10.1111\/jth.13683"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"68.          Droege F, Thangavelu K, Lang S, Geisthoff U. Improvement in hereditary hemorrhagic telangiectasia after treatment with the multi-kinase inhibitor Sunitinib. Ann Hematol. 2016;95(12):2077-2078. https:\/\/doi.org\/10.1007\/s00277-016-2796-6","DOI":"10.1007\/s00277-016-2796-6"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"69.          Faughnan ME, Lui YW, Wirth JA, Pugash RA, Redelmeier DA, Hyland RH, et al. Diffuse pulmonary arteriovenous malformations: characteristics and prognosis. Chest. 2000;117(1):31-38. https:\/\/doi.org\/10.1378\/chest.117.1.31","DOI":"10.1378\/chest.117.1.31"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"70.          Dupuis O, Delagrange L, Dupuis-Girod S. Hereditary haemorrhagic telangiectasia and pregnancy: a review of the literature. Orphanet J Rare Dis. 2020;15(1):5. https:\/\/doi.org\/10.1186\/s13023-019-1286-z","DOI":"10.1186\/s13023-019-1286-z"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"71.          Napso T, Yong HEJ, Lopez-Tello J, Sferruzzi-Perri AN. The Role of Placental Hormones in Mediating Maternal Adaptations to Support Pregnancy and Lactation. Front Physiol. 2018;9:1091. https:\/\/doi.org\/10.3389\/fphys.2018.01091","DOI":"10.3389\/fphys.2018.01091"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"72.          de Gussem EM, Lausman AY, Beder AJ, Edwards CP, Blanker MH, Terbrugge KG, et al. Outcomes of pregnancy in women with hereditary hemorrhagic telangiectasia. Obstet Gynecol. 2014;123(3):514-520. https:\/\/doi.org\/10.1097\/AOG.0000000000000120","DOI":"10.1097\/AOG.0000000000000120"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"73.          Bari O, Cohen PR. Hereditary hemorrhagic telangiectasia and pregnancy: potential adverse events and pregnancy outcomes. Int J Womens Health. 2017;9:373-378. https:\/\/doi.org\/10.2147\/IJWH.S131585","DOI":"10.2147\/IJWH.S131585"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"74.          Chizinga M, Rudkovskaia AA, Henderson K, Pollak J, Garcia-Tsao G, Young LH, et al. Pulmonary Hypertension Prevalence and Prognosis in a Cohort of Patients with Hereditary Hemorrhagic Telangiectasia Undergoing Embolization of Pulmonary Arteriovenous Malformations. Am J Respir Crit Care Med. 2017;196(10):1353-1356. https:\/\/doi.org\/10.1164\/rccm.201702-0267LE","DOI":"10.1164\/rccm.201702-0267LE"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"75.          Bonderman D, Nowotny R, Skoro-Sajer N, Adlbrecht C, Lang IM. Bosentan therapy for pulmonary arterial hypertension associated with hereditary haemorrhagic telangiectasia. Eur J Clin Invest. 2006;36 Suppl 3:71-72. https:\/\/doi.org\/10.1111\/j.1365-2362.2006.01683.x","DOI":"10.1111\/j.1365-2362.2006.01683.x"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"76.          Jiang R, Gong SG, Pudasaini B, Zhao QH, Wang L, He JM, et al. Diffuse Pulmonary Arteriovenous Fistulas With Pulmonary Arterial Hypertension: Case Report and Review. Medicine (Baltimore). 2016;95(14):e3177. https:\/\/doi.org\/10.1097\/MD.0000000000003177","DOI":"10.1097\/MD.0000000000003177"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"77.          Kowalczyk L, Bartsch R, Singer CF, Farr A. Adverse Events of Trastuzumab Emtansine (T-DM1) in the Treatment of HER2-Positive Breast Cancer Patients. Breast Care (Basel). 2017;12(6):401-408. https:\/\/doi.org\/10.1159\/000480492","DOI":"10.1159\/000480492"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"78.          Kwon Y, Gomberg-Maitland M, Pritzker M, Thenappan T. Telangiectasia and Pulmonary Arterial Hypertension Following Treatment With Trastuzumab Emtansine: A Case Report. Chest. 2016;149(4):e103-e105. https:\/\/doi.org\/10.1016\/j.chest.2015.09.008","DOI":"10.1016\/j.chest.2015.09.008"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"79.          Hsu CC, Kwan GN, Evans-Barns H, van Driel ML. Embolisation for pulmonary arteriovenous malformation. Cochrane Database Syst Rev. 2018;1(1):CD008017. https:\/\/doi.org\/10.1002\/14651858.CD008017.pub5","DOI":"10.1002\/14651858.CD008017.pub5"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"80.          Shovlin CL, Buscarini E, Kjeldsen AD, Mager HJ, Sabba C, Droege F, et al. European Re-ference Network For Rare Vascular Diseases (VASCERN) Outcome Measures For He-reditary Haemorrhagic Telangiectasia (HHT). Orphanet J Rare Dis. 2018;13(1):136. https:\/\/doi.org\/10.1186\/s13023-018-0850-2","DOI":"10.1186\/s13023-018-0850-2"}],"container-title":["Jornal Brasileiro de Pneumologia"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T15:17:27Z","timestamp":1681312647000},"score":1,"resource":{"primary":{"URL":"https:\/\/jornaldepneumologia.com.br\/details\/3822\/en-US\/update-on-pulmonary-arteriovenous-malformations"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,12]]},"references-count":80,"URL":"https:\/\/doi.org\/10.36416\/1806-3756\/e20220359","relation":{},"ISSN":["1806-3756"],"issn-type":[{"value":"1806-3756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,12]]}}}